Why the study?
Although proton pump inhibitors reduce upper gastrointestinal bleeding in patients taking oral anticoagulants, evidence was lacking on the safety and effectiveness of oral anticoagulants when co-administered with PPIs.
Do NOACs reduce the risk of upper gastrointestinal bleeding compared to warfarin in patients on oral anticoagulant and proton pump inhibitor co-therapy?
Do NOACs reduce the risk of upper gastrointestinal bleeding compared to warfarin in patients on oral anticoagulant and proton pump inhibitor co-therapy?
In patients requiring oral anticoagulation and proton pump inhibitor co-therapy, NOACs are associated with a significantly lower risk of major upper gastrointestinal bleeding and mortality compared to warfarin.
NOAC-PPI co-therapy was associated with lower upper GI bleeding and mortality versus warfarin-PPI; supports preference for NOACs but leaves open need for randomized confirmation.
BACKGROUND: Proton pump inhibitors (PPIs) are known to reduce the risk of upper gastrointestinal bleeding in patients on oral anticoagulants, and patients are increasingly on oral anticoagulants and PPI co-therapy. However, evidence is lacking on the safety and effectiveness of oral anticoagulants when co-administered with PPIs. METHODS: Among patients initiating oral anticoagulants (warfarin and non-vitamin K antagonist oral anticoagulants [NOACs], i.e. rivaroxaban, dabigatran, apixaban, and edoxaban) during 2013-2017, those concomitantly prescribed PPIs were identified (n = 19,851). The primary endpoint was hospitalization for major upper gastrointestinal bleeding, and secondary endpoints were death and ischemic stroke. RESULTS: During a mean 1.4 years of follow-up, the primary endpoint occurred in 512 (2.58%) patients. Overall, NOACs were associated with lower upper gastrointestinal bleeding risk after adjustment for age, sex, comorbidities and concomitant medications (adjusted hazard ratio 0.78, 95% confidence interval 0.65-0.94), compared to warfarin. There was no significant difference in upper gastrointestinal bleeding risk among the individual NOACs. This trend of reduced risk for upper gastrointestinal bleeding in NOACs compared to warfarin was consistent for both regular and reduced doses, throughout bleeding risk groups, and other subgroup analyses. NOACs were also associated with lower risk of death compared to warfarin. The risk for ischemic stroke was not significantly different among the oral anticoagulants in patients with atrial fibrillation. CONCLUSION: In patients on oral anticoagulant and PPI co-therapy, NOACs were associated with lower risk of upper gastrointestinal bleeding and mortality compared to warfarin, while there was no difference among the oral anticoagulants for stroke prevention. In patients on PPI therapy, NOACs may preferred over warfarin for decreasing risk of upper gastrointestinal bleeding and mortality.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: